Patient Age (yrs); Sex Clinical Features Cancer VGKC Monitoring (days) VGKC Titer (nmol/L) Normal <0.02nmol/L CSF Protein Results (mg/dL) Normal 15-60mg/dL Treatment AEDS MRI Hypothalamic Involvement on MRI
1 93F Altered mental status No Initial 0.13 57 None None Global atrophy, laminar necrosis left parietal lobe No
2 60M Autonomic seizure No Initial 1.58 NA IVIG LCM, LTG Bilateral mesial temporal lobe hyperintensity Yes
        54 4.22   PLEX      
        161 15.8          
        273 1.94          
3 53F Altered mental status, depression No Initial 0.76 69 IVMP x5 days, IVIG x5 days LEV, LCM Bilateral hyperintensity in the restiform bodies No
4 55M Altered mental status No Initial 3.89 101 IVMP x5 days, PLEX x5 days ZON, LEV, LCM Right unilateral mesial temporal lobe hyperintensity No
5 37F Complex partial seizure No Initial 2.8 47 IVIG x3 days, IVMP x3 days, PLEX x5 days VPA, LEV, PHT Bilateral basal ganglia/hippocampus hyperintensity Yes
        408 0.77          
6 85M Altered mental status, seizure No Initial 0.692 48 IVMP x5 days, PLEX x3 days/week for 2 weeks VPA, LEV, TPM Right unilateral mesial temporal lobe hyperintensity Yes
Abbreviations: M=male, F=female, VGKC=voltage gated potassium channel antibody, CSF=cerebrospinal fluid, IVMP=1 gram of intravenous methylprednisolone, IVIG=0.4g/kg/d of intravenous immunoglobulin, PLEX=plasma exchange
Table 1: Characteristics of patients with serology positive for VGKC antibodies.